Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stellar Performance | Stryker's Q3 2024 results showcase exceptional organic growth of 11.5%, surpassing expectations and driving positive analyst revisions |
Innovation Leade | Explore Stryker's cutting-edge product pipeline, including robotic surgery platforms and minimally invasive technologies driving market leadership |
Global Expansion | Delve into Stryker's international growth strategy, with strong performance in Europe, emerging markets, and Asia-Pacific regions |
Analyst Outlook | Analyst price targets range from $360 to $418, reflecting confidence in Stryker's growth potential and market positioning |
Metrics to compare | SYK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYKPeersSector | |
---|---|---|---|---|
P/E Ratio | 39.8x | −7.9x | −0.6x | |
PEG Ratio | 1.04 | 0.18 | 0.00 | |
Price/Book | 7.1x | 4.1x | 2.6x | |
Price / LTM Sales | 6.5x | 2.8x | 3.2x | |
Upside (Analyst Target) | 7.7% | 58.7% | 45.4% | |
Fair Value Upside | Unlock | 5.8% | 7.7% | Unlock |